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Abstract
The cellular and molecular mechanisms underlying the pathogenesis of cataracts leading to visual impairment remain
poorly understood. In recent studies, several mutations in the cytoplasmic sterile-a-motif (SAM) domain of human EPHA2 on
chromosome 1p36 have been associated with hereditary cataracts in several families. Here, we have investigated how these
SAM domain mutations affect EPHA2 activity. We showed that the SAM domain mutations dramatically destabilized the
EPHA2 protein in a proteasome-dependent pathway, as evidenced by the increase of EPHA2 receptor levels in the presence
of the proteasome inhibitor MG132. In addition, the expression of wild-type EPHA2 promoted the migration of the mouse
lens epithelial aTN4-1 cells in the absence of ligand stimulation, whereas the mutants exhibited significantly reduced
activity. In contrast, stimulation of EPHA2 with its ligand ephrin-A5 eradicates the enhancement of cell migration
accompanied by Akt activation. Taken together, our studies suggest that the SAM domain of the EPHA2 protein plays
critical roles in enhancing the stability of EPHA2 by modulating the proteasome-dependent process. Furthermore, activation
of Akt switches EPHA2 from promoting to inhibiting cell migration upon ephrin-A5 binding. Our results provide the first
report of multiple EPHA2 cataract mutations contributing to the destabilization of the receptor and causing the loss of cell
migration activity.
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Introduction
Cataract,the lensopacitydisease,istheleadingcauseofblindness
in the world, accounting for 48% of the cases [1]. Congenital
cataract (CC) is one of the common causes of visual impairment in
infants up to 25% [2]. Recent studies have examined the excess
clustering of the disease in families with a high risk for cataract
developments [3]. In addition, as much as 40% of early-onset
cataracts may have a genetic basis [4]. Genetic studies have
identified numerous underlying mutations including crystalline
genes (CRYAA, CRYAB, CRYBB1, CRYBB2, CRYBB3, CRYBA3/A1,
CRYBA4, CRYGC, GRYGD,a n dCRYGS) [5–13], connexin genes
(GJA3, GJA8) [14,15], and intermediate-filament-like factors (VIM)
[16]. Recent genetic analyses revealed an additional novel pathway
for cataract formation, mediated by mutations in the Eph receptor
tyrosine kinase-type A2 (EPHA2) [17–20].
Human EPHA2 resides within the critical region on chromo-
some 1p36 that was previously defined in an Australian family
with autosomal dominant total congenital cataracts [21,22]. A
recent study on the variations in the EPHA2 receptor tyrosine
kinase gene within this region has identified a missense mutation
c.2842G.T which substitutes an amino-acid from glycine to
tryptophan at codon 948 (GGG.TGG: p.G948W) for autosomal
dominant posterior polar cataracts in Caucasians [20]. In addition,
other recent findings identified missense [c.2819C.T (p.T940I)
in a Chinese family], frameshift [c.2915_2916delTG
(p.V972GfsX39) in a British family] and splicing (c.2826-9G.A
in an Australian family) mutations in EPHA2 in three independent
families developing CC from different ancestral groups [19]. All of
these mutations are located in the cytoplasmic sterile-a-motif
(SAM) domain at the C-terminus of EPHA2 [20,23,24], suggesting
that the SAM domain of EPHA2 may have an important role in
the regulation of EPHA2 function and lens development.
The SAM domain is a conserved protein module in many key
regulatory proteins, scaffolding proteins, and transcription factors.
Mutations in the SAM domain have been observed to cause
several human diseases [19,20,25–34]. For example, SAM domain
mutations in the TP63 have been shown to affect SUMO-1-
mediated regulation which would influence the protein stability
causing ectodermal dysplasia syndromes [31,32]. These defects are
derived from increased TP63 ubiquitination as a result of the SAM
domain mutation [29]. The 12p13 ETV6 (TEL: translocation ETS
leukemia) SAM domain mutations block polymerization of ETV6-
NTRK3 (EN) and transformation activity [26,33]. The impor-
tance of this domain has led to numerous studies on the structure
and stoichiometry of SAM domain complexes [19]. However,
although SAM domains are capable of forming both homo- and
hetero-oligomers in vitro, it remains unclear how SAM domains
mediate protein interactions and what mechanisms regulate its
association in vitro or in vivo. The presence of a conserved SAM
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indicates that it may play a role in regulating Eph receptor
signaling. Since SAM domains facilitate protein-protein interac-
tions [24] through homo- and hetero-oligomerization with other
SAM domains, it is possible that EphA2 SAM domain mutations
interfere with receptor oligomerization or clustering into higher-
order complexes essential for physiologic signaling [23].
In the human genome, there are 14 Eph-coding genes (9
EPHAs and 5 EPHBs) and 8 ephrin ligand-coding genes (5 EFNAs
and 3 EFNBs) [35]. Eph-related receptor tyrosine kinases (RTKs)
have been implicated in the control of axon guidance, cell
migration, angiogenesis, and patterning of the nervous system.
Our previous studies showed that ephrin-A5 acts as a ligand for
EphA2 in the lens, and the loss of ephrin-A5 function leads to
cataracts in mice [36]. Additionally, ephrin-A5 interacts with the
EphA2 receptor to regulate the adherens junction complex by
enhancing recruitment of b-catenin to N-cadherin [36]. However,
a molecular mechanism of EPHA2 signaling through the SAM
domain that regulates lens development remains unknown. Here,
we show that the EPHA2 SAM domain is required for protein
stability and that the receptor utilizes both ligand-dependent and
independent mechanisms to regulate lens epithelial cell biology.
Results
Mutations in the SAM domain of EPHA2 gene reduce
protein levels
Our previous observations on the role of the ephrinA5/EphA2
molecules on lens development [36] suggest that EphA2 may act
as a critical mediator in lens function. Consistent with our
hypothesis, it has been shown that mutations in the EPHA2 gene
within human chromosome 1p36 region lead to cataracts [17–
20,37]. Interestingly, four of the known mutations within EPHA2
are located in the SAM domain of the C-terminal region of
EPHA2 (Figure 1A) that serves as a potential protein interaction
site [19,20,23,24]. To examine the consequences of these
mutations, we generated four mutant EPHA2 genes: the missense
mutants c.2819C.T (p.T940I) and c.2842G.T (p.G948W), the
frameshift mutant c.2915_2916delTG (p.V972GfsX39), and the
splicing mutant c.2826-9G.A (Figure 1A). In the c.2819C.T
EPHA2 mutant, isoleucine replaces the wild-type threonine at
residue 940 between H-3 and H-4 segments in the SAM domain
[19]. The missense mutant c.2842G.T has a G?T mutation of
codon 948 (GGG.TGG) resulting in the missense substitution of
glycine by tryptophan [20]. The c.2915_2916delTG mutant has a
deletion of 2 bp in exon 17 resulting in a mutant EPHA2 protein
with a novel C-terminal polypeptide of 39 amino acid residues.
The c.2826-9G.A substitution creates a novel splice acceptor site
which adds an intronic sequence into the mRNA generating a
novel 71 amino acid residues at the C-terminus, of which the last
39 residues are identical to that of the novel polypeptide produced
by the c.2915_2916delTG frameshift mutation [19].
To investigate whether the EPHA2 SAM domain mutations
affect EPHA2 expression, we examined EPHA2 protein levels.
Wild-type and mutant EPHA2 genes were transfected into
HEK293T and mouse lens epithelial aTN4-1 cells. Wild-type
EPHA2 is expressed at high levels in both HEK293T and aTN4-1
cells, while the mutant EPHA2 genes, c.2915_2916delTG,
c.2826G.A and c. 2842G.T, showed low levels compared to
the wild-type (Figure 1B). However, one of the mutant proteins,
c.2819C.T, did not show a significantly lower level of expression
from that of the wild-type protein, although it appeared to be
somewhat reduced. We next examined whether these differences
were due to the differences in transcription. Semi-quantitative
(Figure 1C) and real-time RT-PCR (Figure 1D) reactions were used
to investigate the mRNA levels. After transfection into HEK293T
cells, PCR reactions for wild-type and mutant EPHA2 genes were
performed using total RNA of the transfected cells, and EPHA2
PCR products were normalized to GAPDH transcript levels. No
differences were found in mRNA level between the wild-type and
mutants (Figure 1C,D), suggesting that these SAM domain
mutations affect EPHA2 protein levels posttranscriptionally. We
also expressed the wild-type and mutant EPHA2 SAM domain
constructs as GST-fusion proteins in E. coli and found that the
solubility of the mutant proteins was significantly reduced (Figure
S1A,B) indicating an alteration of protein conformation. These
results together suggest that mutations in the SAM domain of
EPHA2 receptor reduce protein stability, and the reduced mutant
protein levels may also in part, be a result of defective protein
synthesis or maturation related to their altered conformation.
We also investigated EPHA2 protein expression using ligand-
mediated immunofluore- scence staining. Detectable binding of
ephrin-A5 was observed in EphA2
2/2 MEF cells expressing wild-
type and mutant EPHA2 genes (Figure 2). Wild-type EPHA2
showed evenly distributed small protein aggregates throughout the
cells (Figure 2). In contrast, EPHA2 mutants exhibited large protein
aggregates, suggesting that the mutations in the SAM domain lead
to enhanced protein aggregation, consistent with decreased GST-
SAM domain fusion protein solubility in E. coli (Figure S1B).
The ubiquitin-proteasome pathway mediates
degradation of EPHA2 mutants
To determine whether the SAM domain mutations reduce the
half-life of EPHA2 protein, we examined effects of cycloheximide
(CHX), a protein synthesis inhibitor. HEK293T cells expressing
wild-type and mutant EPHA2 genes were treated with 50 mg/mL
CHX to block new protein synthesis. EPHA2 proteins with
mutations in the SAM domain showed more rapid degradation
kinetics compared to the wild-type (Figure 3A). The half-life of
wild-type EPHA2 is approximately 3 hours (Figure 3B), whereas
the half-life of the mutant proteins has been reduced to less than
1 hour (Figure 3A,B). These results demonstrate that mutations in
the SAM domain result in rapid EPHA2 proteolysis.
To investigate whether EPHA2 degradation is mediated
through proteasomal and lysosomal pathways, cells were treated
with either the specific proteasome inhibitor MG132 or the
lysosomal proton pump inhibitor bafilomycin A1. In the presence
of 10 mM MG132, the expression levels of mutant EPHA2
proteins gradually increased over time (Figure 3A,B). Co-
treatment with CHX and MG132 also largely prevented
degradation of EPHA2 proteins (Figure S2A,B). In contrast,
bafilomycin A1 did not affect the levels of EPHA2 proteins (Figure
S3). These results indicate that EPHA2 proteins are degraded by
proteasomes rather than lysosomes, and that the SAM domain is
critical in modulating the degradation.
Proteasomal inhibition is normally associated with the accumu-
lation of polyubiquitinylation on proteins. To confirm EPHA2 is
degraded via the ubiquitin-mediated proteasomal pathway, wild-
type and mutant EPHA2 genes were cotransfected with HA-tagged
ubiquitin (HA-Ub) in the presense of MG132. The EPHA2
proteins were then immunoprecipitated with anti-EphA2 antibody
and analyzed with western blotting for the presence of ubiquitin
using an anti-HA antibody. The anti-HA antibody detected an
increase in the intensity of high-molecular-mass EPHA2 proteins
(Figure 3C), suggesting that the mutant proteins had increased
polyubiquitination. Taken together, our data indicate that these
particular mutations in the SAM domain of the EPHA2 receptor
enhance proteasome-mediated EPHA2 protein degradation.
EPHA2 Cataract Mutations
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e36564Figure 1. EPHA2 cataract mutations in the SAM domain. (A) Schematic diagram showing the domains of EPHA2 receptor and the locations of
four SAM domain mutations found in human cataracts (c.2819C.T; c.2915_2916delTG; c.2826-9G.A; and c.2842G.T) in the EPHA2 gene. FN-III:
fibronectin type-III domain; TM: transmembrane domain; Kinase: protein tyrosine kinase domain; SAM: sterile-a-motif domain; P: PDZ-binding motif.
The SAM domain comprises 5 a-hecices (H1–5). (B) Reduction of mutant EPHA2 protein levels in transfected cells expressing EPHA2 mutants. Protein
levels of EPHA2 mutants are decreased in both HEK293T and aTN4-1 cells. The blot was reprobed with anti-a-tubulin as a loading control. The graphs
represent the quantification of relative band intensity of EphA2 as connected by the levels of a-tubulin from three independent experiments. Total
EphA2 protein band intensity was determined using ImageJ software. Mean values are presented with +S.D as indicated. Statistical differences
between multiple groups were analyzed using one-way analysis of variance (ANOVA). ***, P,0.001; **, P,0.01; *, P,0.05; and ns, not significant.
Values of P,0.05 were considered to be statistically significant. (C, D) No difference between wild-type and mutant EPHA2 genes in transcription
levels. (C) Semi-quantitative RT-PCR and (D) Real-time PCR for wild-type and mutant EPHA2 genes were performed using total RNA, isolated from
transfected HEK293T cells. GAPDH transcript levels are used as controls. The graphs represent the quantification of western blots from three
independent experiments.
doi:10.1371/journal.pone.0036564.g001
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of EPHA2 mutants
One important question is whether the EPHA2 mutants can still
be activated by ephrin-A5. To address this question, EPHA2 wild-
type and mutant genes were transfected into HEK293T and
aTN4-1 cells, and the cells were stimulated with clustered
recombinant ephrin-A5-Fc at 37uC for 30 minutes. The cell
lysates were analysed with two phospho-specific antibodies: anti-
phospho-Tyrosine (4G10) and anti-phospho-EphA2. EPHA2 wild-
type and mutants showed similar tyrosine phosphorylation in
response of ephrin-A5 ligand (Figure 4). This analysis showed that
all mutants were autophosphorylated, although the levels were
lower than the wild-type due to reduced protein concentration
(Figure 4A,B). Ephrin-A5 stimulation further enhanced EPHA2
tyrosine phosphorylation. To confirm that EPHA2 is specifically
phosphorylated, we probed the cell lysates with an anti-phospho-
EphA2 (Tyr594) antibody, which detects transfected levels of
EPHA2 proteins only when phosphorylated on Tyr594 and does
not cross-reacted with other activated protein tyrosine kinases
[38]. As shown in Figure 4A and Figure 4B, ephrin-A5 also
enhanced EPHA2 Y594 phosphorylation in both HEK293T and
aTN4-1. Quantification of intensity of the phosphorylated EPHA2
after protein level corrections showed similar activity between the
wild-type and mutant EPHA2 proteins, although the mutants had
reduced protein expression level (Figure 4C).
EPHA2 cataract mutations result in the loss of the ability
to promote cell migration
To examine how the cataract mutations affect EPHA2 function,
we investigated EPHA2 regulation on cell migration using the
wound-healing assay, a common method in analyzing cell
migration. A confluent cell monolayer was wounded using a
pipette tip, introducing a cell-free area, and the migration of cells
into the wound was monitored by capturing images at the
indicated time points. In the absence of ephrin-A5 stimulation,
wild-type EPHA2 promoted cell migration, while EPHA2
mutations in the SAM domain greatly reduced this ability
(Figure 5A). Cells expressing wild-type EPHA2 began to migrate
into the wound at 24 hours, while ephrin-A5 treatment signifi-
cantly impaired the EPHA2-induced migration. Wound-healing
assays were also quantified by measuring the distance by which
transfected cells migrated into the cell-free region. Cells expressing
wild-type EPHA2 migrated markedly faster than the mutants,
occupying 51.25% (3.075 mm/6 mm) of the cell-free area after
24 hours and to 69.17% (4.15 mm/6 mm) after 48 hours
(Figure 5B). The cataract mutations reduced the ability of EPHA2
to promote cell migration (Figure 5A,B). Although the wild-type
EPHA2 promoted cell migration, treatment with ephrin-A5
impaired EPHA2-mediated cell migration (Figure 5A,B). Similar
results were obtained using HEK293A cells (Figure S4A,B). In
addition, statistical analysis showed there were significant
Figure 2. Subcellular localization of the wild-type and mutant EPHA2 receptors on transfected EphA2
2/2 MEF (E13.5) cells. EphA2
knockout MEF cells expressing wild-type or mutant EPHA2 were incubated with clustered ephrin-A5-Fc before fixation and treated with anti-Fc
antibodies (red). After washing with PBS, cells were counterstained with anti-EphA2 antibody (green). Images were captured using a Nikon Eclipse C1
confocal microscope. Scale bar, 50 mm.
doi:10.1371/journal.pone.0036564.g002
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groups (Figure 5B and Figure S4). The effects of mutant EPHA2
genes were also statistically different compared to that of mock-
transfected aTN4-1 cells (Figure 5B).
These observations demonstrate that EPHA2 promotes cell
migration in the absence of ligand. However, ligand stimulation
resulted in a switch of EPHA2 function, turning promotion to
inhibition of cell migration.
EPHA2 SAM domain mutations reduce Akt activation
To assess whether the SAM domain mutations affect EPHA2
biochemical functions, we determined the effects of EPHA2 on
Akt and extracellular signal-regulated kinase (Erk) 1/2 signaling
[18,39,40]. HEK293T cells transfected with wild-type and mutant
EPHA2 genes were serum-starved for 24 hours, then treated with
2 mg/mL ephrin-A5-Fc at the indicated time points. Stimulated
cells were lysed and examined for Akt and Erk activation. Ephrin-
Figure 3. EPHA2 degradation is mediated by proteasomal pathway. (A) Mutant EPHA2 proteins have a reduced half-life. HEK293T cells were
treated for indicated time with the protein biosynthesis inhibitor CHX (50 mg/mL) or the proteasome inhibitor MG132 (10 mM). Cell lysates were
immunoblotted with anti-EphA2 antibody. Lysates were resolved by SDS-PAGE and western blot analysis was performed using indicated antibodies
as described in the Materials and Methods. The blot was reprobed with anti-a-tubulin as a loading control. (B) Quantification of EphA2 protein levels
over time. Mean values are presented with +S.D as indicated. (C) EPHA2 mutants have increased ubiquitination. Cells transfected with EPHA2 and
HA-tagged ubiquitin were treated with 10 mM MG132 for 6 hours, and were then lysed. Immunoprecipitated EphA2 was further analyzed with
western blotting using anti-HA antibodies to detect ubiquitinated EphA2 as described in the Materials and Methods. The smear band is characteristic
ubiquitin immunoreactivity. The amount of total EphA2 is shown as a loading control.
doi:10.1371/journal.pone.0036564.g003
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resulted in an increase of Akt phosphorylation at Ser473 in a time-
dependent manner. In contrast, ephrin-A5-induced Akt phos-
phorylation was severely reduced in EPHA2 mutant-transfected
cells after ephrin-A5 stimulation (Figure 6A). Akt phosphorylation
was almost undetectable in cells expressing c.2915_2916delTG,
c.2826-9G.A and c.2842G.T. Similar results were obtained
using aTN4-1 cells (Figure S5A,B). The ability of the various
EphA2 genes to activate Akt closely correlated with the receptor
protein levels, as evidenced by the similar ratios of phospho-Akt
(Ser473) to total EphA2 protein signals (data not shown).
To determine whether the SAM domain mutations affect p44/
p42 mitogen-activated protein kinase (MAPK) phosphorylation,
lysates of HEK293T cell transfected with various EPHA2 genes
were probed with anti-phospho-Thr202/Tyr204 Erk1/2 anti-
body. Ephrin-A5 stimulation of HEK293T cells expressing wild-
type EPHA2 resulted in a robust increase in Erk phosphorylation,
while cells expressing the EPHA2 mutant genes showed little or no
activation (Figure 6B). In addition, the intensity of the phosphor-
ylated Erk1/2 showed also a dependence on EPHA2 protein
expression levels, similar to Akt activity (data not shown).
To examine whether EphA2 inactivation affects activation of
Akt and Erk1/2 in vivo, we analyzed the lenses of postnatal day 22
(P22) EphA2
+/+ and EphA2
2/2 mice. Akt activation was clearly
detected in the wild-type EphA2 mouse lens (Figure 6C).
However, Akt phosphorylation was almost undetectable in
EphA2
2/2 mice. In contrast, levels of phospho-Erk1/2 did not
show any decrease (Figure 6C).
Discussion
EPHA2 is a member of the Eph family receptor tyrosine kinases,
and is strongly expressed in the cortical lens fiber cells. Recent
studies have shown that mutations or deletion of EphA2 gene lead
to cataracts in humans and mice [18–20]. Complementing these
observations, our previous study identified that the loss of ephrin-
A5 also leads to cataracts in mice [36], indicating that EphA2
serves as a receptor for the ligand in maintaining the clarity of the
crystalline lens. The current study aims to define the nature of the
EPHA2 SAM domain mutations. Previous studies showed that the
SAM domains in Eph receptors may have multiple functions
[38,41–46]. The SAM domain of EphB2 receptor can self-
associate and forms oligomers [42,44], although the exact function
is not known at present. In contrast, the SAM domain of EphA4
receptor has been shown to negatively regulate receptor kinase
activity [43], but is not required for topographic mapping in the
brain [41]. This domain has also been shown to mediate
recruitment of downstream signaling molecules [45,46]. A recent
study by Fang et al. showed that the tyrosine 929 in the SAM
domain of EphA2 is required for Ephrin-A1-induced vascular
assembly [38]. Our analysis revealed an additional function in the
maintenance of receptor stability.
EPHA2 SAM domain mutations cause increased receptor
proteolysis
Eph receptors have an extracellular region consisting of an
ephrin-binding domain and two fibronecin type III repeats, and an
intracellular region comprised of a regulatory juxtamembrane
domain, a tyrosine kinase domain, a SAM domain and a PDZ-
binding motif [23]. SAM domains mediate important protein-
protein interactions and are found in a variety of signaling
molecules that exert diverse cellular functions [25]. A highly
conserved SAM domain in the cytoplasmic region of all Eph
receptors is located at the C-terminal region of the receptors and
Figure 4. Tyrosine phosphorylation of EPHA2 receptor by
ephrin-A5 is not affected by SAM domain mutations. (A, B)
Ephrin-A5 ligand stimulates EPHA2 phosphorylation. HEK293T (A) and
aTN4-1 (B) cells were grown to confluence and growth factor-starved
for 24 hours. 2 mg/mL cross-linked ephrin-A5-Fc was then added to the
starvation media and cell lysates were immunoblotted with indicated
antibodies. Western blot analysis was performed as described in the
Materials and Methods. The blot was reprobed with anti-a-tubulin as a
loading control. (C) The ratios of levels of phospho-EphA2 to total
EphA2 are similar between the wild-type and mutant EPHA2 proteins.
The graphs show total band intensity of anti-phospho-EphA2 immu-
noblot to total EphA2 and represent the average of three independent
experiments. Quantification of phospho-EphA2 protein/total EphA2
protein levels was performed using ImageJ software. Mean values are
presented with +S.D as indicated. Statistical differences between
multiple groups were analyzed using one-way analysis of variance
(ANOVA). Values of P,0.05 were considered to be statistically
significant. ns: No statistically significant difference between the two
groups.
doi:10.1371/journal.pone.0036564.g004
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SAM domain of the EPHA2 protein modulates ubiquitinylation
and regulates the stability of the receptor. As a first step to examine
the specific effects of EPHA2 SAM domain mutations, we
investigated the stability of the mutant EPHA2 proteins in two
different cell lines, HEK293T and aTN4-1. Our results show that
Figure 5. SAM domain of EPHA2 is essential for ligand-independent promotion of cell migration. (A) Mutant EPHA2 genes fail to
promote aTN4-1 cell migration. aTN4-1 cells were grown to confluency and serum-starved for 24 hours. A scratch wound was made with a
micropipette tip and the edge of cells was marked. 2 mg/mL cross-linked ephrin-A5-Fc was then added to the starvation media, and cells were
allowed to migrate toward the center of the wound and photographed at the indicated times (representative figure of three independent
experiments). The position of the initial scratch is indicated by dotted lines. Scale bar, 500 mm. (B) Quantification of the effects of EPHA2 genes on
aTN4-1 cell migration. The graphs represent the measurement of migration distance from three independent experiments. Mean values are
presented with +S.D as indicated. Statistical differences were analyzed using one-way analysis of variance (ANOVA) or calculated by a two-tailed
student t-test. Black asterisks, comparison between time 0 and 24 hours and time 0 and 48 hours; Blue asterisks, comparison between the mock
groups and the listed wild-type or mutant EPHA2 genes at 24 or 48 hours; Red asterisks, comparison between untreated and treated conditions at 24
or 48 hours. ***, P,0.001; **, P,0.01; *, P,0.05; and ns, not significant. Values of P,0.05 were considered to be statistically significant.
doi:10.1371/journal.pone.0036564.g005
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e36564the EPHA2 proteins with SAM domain mutations exhibit
increased degradation in a proteasome-dependent pathway, as
treatment with the proteasome inhibitor MG132 enhanced
EPHA2 protein levels. Ubiquitin-mediated proteasomal degrada-
tion pathway plays an important role in regulating a wide variety
of cellular processes, since many proteins are degraded through
Figure 6. Ligand-stimulated EPHA2 activation regulates Akt and Erk activation. (A, B) Mutant EPHA2 proteins exhibit reduced activation
of Akt and Erk by ephrin-A5. HEK293T cells were grown to confluence and serum-starved for 24 hours. 2 mg/mL cross-linked ephrin-A5-Fc was then
added to the starvation media and cell lysates were immunoblotted with anti-phospho-Akt (Ser473) or anti-phospho-Erk (1/2), and then reprobed
with anti-a-tubulin as a loading control. (C) Inactivation of EphA2 gene leads to reduction of Akt activity in mouse lenses. Each lens was prepared
from 22 days old mice and extracted with lysis buffer. Total lens proteins were resolved by SDS-PAGE and western blot analysis was performed using
indicated antibodies as described in the Materials and Methods. The blot was reprobed with anti-a-tubulin as a loading control.
doi:10.1371/journal.pone.0036564.g006
EPHA2 Cataract Mutations
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domain mutations cause cataracts through the reduction of
EPHA2 protein levels.
Although the SAM domain modulates EPHA2 stability and
protein solubility, it cannot be ruled out that the PDZ-binding
motif may also contribute to EPHA2 stability, since the two
mutants without the PDZ-binding domain, c.2915_2916delTG
and c.2826-9G.A, showed lower steady state protein levels.
Mutations in the SAM domain affect EPHA2 protein
solubility and subcellular localization
Many human diseases such as Alzheimer’s and Parkinson’s
diseases as well as cataracts, have been demonstrated as ‘‘protein
condensation diseases’’, in which the pathogenic proteins form
insoluble aggregates [50]. It has been shown also previously that
the change of sequence parameters by mutations can affect protein
expression and solubility in vivo [50]. To gain insights into the
effects of the cataract mutations on protein solubility, we generated
SAM domain fusion proteins from the wild-type and mutant
EPHA2 receptors. Interestingly, all the GST-SAM domain mutant
fusion proteins were insoluble in contrast to the wild-type GST-
SAM domain fusion protein. These results indicate that SAM
domain mutations influence protein stability and degradation rate
through changes of solubility and folding efficiency. Several
pathogenic proteins have been reported to have mutations in
specific domains which induce aggregate formation and deplete
the proteins from their normal cellular environment due to
incorrect protein folding [51,52]. Indeed we also observed that the
mutations in the SAM domain of EPHA2 alter the patterns of
subcellular distribution. The mutant proteins form much bigger
aggregates than the wild-type. These observations support the
notion that the EPHA2 cataract mutations induce protein
misfolding leading to instability, which may lead to cellular
disorganization and eventual lens opacity. Recent studies have
shown that the solubility of several cataract-linked mutants of
human cD-crystallin is severely compromised as a result of the
mutations [50]. Well known examples are the R36S and the P23T
mutants of human cD-crystallin, which can spontaneously
crystallized at very low concentrations in vitro as a result of the
lowered solubility of the mutant protein [50]. Similarly, mutant
EPHA2 receptors form large protein aggregates, consistent with an
insolubility issue.
EPHA2 regulates cell migration
It has been well established that wild-type EphA2 regulates cell
migration, proliferation and invasion in a number of cell types
[53–59]. Given the wealth of information linking EphA2 to cell
migration, we evaluated the functional effects of the EPHA2 SAM
domain mutations using the wound-healing assay. We showed that
EPHA2 promotes cell migration in the absence of ligand
stimulation, and that the SAM domain mutations diminish this
activity, possibly due to the reduction of EPHA2 protein levels.
Statistical analysis showed that there were significant differences
between the wild-type and mutant EPHA2 genes. Similar
enhancement effects in cell migration were reported following
EphA2 expression in other cell types, including MDA-MB-231
breast cancer cells [59], PC3 carcinoma cells [60], U373
glioblastoma cells, and U87 glioblastoma cells [57]. Inactivation
of EphA2 has also been shown to impair cell migration [58,61].
For example, EphA2-deficient murine pulmonary microvascular
(MPMEC) endothelial cells have impaired angiogenesis [58,61].
Ligand-independent promotion of cell migration by EphA2 is
likely mediated through interaction with Ephexin4 and the
eventual activation of Rac1 [59].
Ephrin ligand binding induces Eph receptor phosphorylation
and activation [53,56,57,61]. The activation of EphA2 has been
shown to negatively regulate cell migration [57,60,62], prolifera-
tion [53] and invasion [54–56] in a number of cell lines including
U373, U87, A172, PC3, MDA-MB-231, MDA-MB-435,
MCF10A, Capan2, G48a, U87 and U251. We also observed that
stimulation of EPHA2 with ephrin-A5 resulted in the inhibition of
migration of HEK293T and aTN4-1 cells. Although EphA2
activation inhibits cell migration in these studies, the opposite
effects have also been reported [58,61,63]. Brantley-Sieders et al.,
showed that stimulation of lung microvascular endothelial cells
(MPMEC) and bovine pulmonary microvascular endothelial cells
(BPMEC) with ephrin-A1 induces cell migration [58,61]. In
human cardiac stem cells (CSC), ephrin-A1 promotes cell
migration and enhances cardiac repair [63]. Taken together, our
results are consistent with previous studies showing that EPHA2 is
a major regulator of cell migration, and that the effects depend on
whether the ligand is present and the cellular context.
Akt activation serves as a switch for EPHA2 function in
cell migration
Mechanism underlying EPHA2 suppression of cell migration
after ligand stimulation remains incompletely defined. The
phosphoinositide 3-kinase (PI3K) signaling pathway has been
shown to regulate cell growth, proliferation and migration [62,64].
Akt and Akt-related serine-threonine kinases are activated by
ligand stimulated growth factor receptor signaling in a PI3K-
dependent manner [64]. We have shown here that activation of
EPHA2 by ephrin-A5 in both aTN4-1 and HEK293 cells resulted
in Akt activation, which correlates with inhibition of cell
migration. Akt activation has been shown to inhibit migration
and invasion of MDA-MB-231, MDA-MB-435 and SUM-159-PT
breast cancer cells [65]. Another recent study has shown that
down-regulation of Akt1 enhanced epidermal growth factor
(EGF)-stimulated cell migration in MCF-10A breast cancer cells
[66]. These results are consistent with our observation that
activation of Akt mediates the inhibitory effects on migration.
Thus, Akt activation serves as molecular switch for EphA2
function in cell migration.
The effects of EphA2 activation on Akt activity can vary
depending on the cellular context. A number of studies have
shown that stimulation of EphA2 by ephrin-A1 resulted in
inhibition of Akt activity in certain cell lines (U87, U251, A172,
MCF7, G48a, ES2, HEYA8 and corneal epithelial cells)
[39,54,57,62]. However, Akt is activated following ephrin-A1
stimulation in a number of other cell lines (B16, LNCaP, BxPC-3,
PANC-1 and MIA PaCa-2) [39,67]. Consistent with these latter
studies, we observed Akt activation by ephrin-A5 stimulation, and
found that Akt (Ser473) became highly phosphorylated in response
to the addition of the ligand. The molecular mechanisms
underlying this activation need further investigation. We also
showed Akt activation depends on EphA2 expression levels, and
reduced Akt activation may be responsible at least in part for
cataract development in patients with EphA2 SAM domain
mutations, since our in vivo studies reveal that Akt activation was
significantly reduced in EphA2 knockout mouse lens. Thus, the
ability of EPHA2 to cause Akt dephosphorylation or phosphor-
ylation appears to depend on cell specific environment, and there
may be kinase-dependent and -independent pathways that
regulate Akt activity.
In sum, our studies show that mutations in the SAM domain of
EPHA2 receptor induce EPHA2 protein instability. In addition,
ephrin-A5 stimulation induces Akt activation, which in turn
suppresses cell migration. These observations provide new insights
EPHA2 Cataract Mutations
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Materials and Methods
Ethics statement
Animal studies were performed under standard conditions and
treated in accordance with the Guidelines for the Animal Care
and Use Committee at Rutgers University and ARVO Statement
for the Use of Animals in Opthalmic and Vision Research
(Rutgers approval ID number #93-052).
Mice and tissue extraction
The EphA2
2/2 [68] mice were kindly provided by Dr.
Bingcheng Wang (Case Western Reserve University School of
Medicine, Cleveland, Ohio, USA). All animals used were 22 days
old in this study. For tissue extraction, lenses were dissected from
mouse eyes and homogenized in ice-cold lysis buffer containing
50 mMTris-HCl (pH 8.0), 150 mM NaCl, 1%NP-40, 100 mg/mL
phenylmethylsulfonyl fluoride (PMSF), 1 mg/mL aprotinin,
10 mg/mL leupeptin, and 1 mM Na3VO4. The samples were
cleared by centrifugation at 13,000 g for 2 minutes and used in
western blot analysis.
Cell culture and transfection
Human embryonic kidney 293T (HEK293T) cells obtained
from American Type Culture Collection (ATCC), and mouse lens
epithelial aTN4-1 cells [69] were generously provided by Dr.
Bingcheng Wang (Case Western Reserve University School of
Medicine, Cleveland, Ohio, USA). Cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich,
USA) containing 4500 mg/L glucose/L, 584 mg/L L-glutamine/
L with 10% fetal bovine serum (FBS) and 1% Penicillin-
Streptomycin solution (10000 units penicillin and 10 mg
streptomycin/mL in 0.9% NaCl, Sigma-Aldrich, USA) at 37uC.
Primary mouse embryonic fibroblasts (MEFs) were isolated from
EphA2
2/2 E13.5 embryos and cultured in DMEM supplemented
with 10% FBS [70]. Cells from passage 2 were used for
transfection. Transient transfection was performed using Lipofec-
tamine 2000 (Invitrogen, Carlsbad, CA, USA) following the
manufacturer’s instructions. Protein levels were evaluated by
immunoblotting 2 days after transfection.
Expression of EPHA2 genes
The human EPHA2 wild-type (GenBank NM_004431.3) and
c.2842G.T were cloned using PCR previously [19]. Three other
mutant cDNAs (c.2819C.T; c.2915_2916delTG; c.2826-9G.A)
were generated by DNA synthesis (GeneScript USA Inc.). All
cDNAs were cloned into the eukaryotic expression vector
pcDNA3.1 (Invitrogen, Carlsbad, CA, USA). All mutations were
verified by DNA sequencing.
Antibodies and reagents
Antibodies used for immunoblot are from the following sources:
anti-phospho-EphA2 (Tyr594) (1:500, #3970), anti-Akt (1:1000,
#4691S), anti-phospho-Akt (Ser473) (1:1000, #9271S), anti-
Erk1/2 (1:1000, #4695S), anti-phospho-Erk1/2 (1:1000,
#9101S) and anti-HA-Tag (1:1000, #2367) from Cell Signaling
Technology (Beverly, MA, USA); anti-EphA2 (1:500, #E1026),
anti-a-tubulin (1:5000, #T6074), cycloheximide (CHX) (#C4859)
and MG132 (Z-Leu-Leu-Leu-al) (#C2211) from Sigma-Aldrich
(USA); bafilomycin A1 (#ab120497) and anti-EphA2 (1:1000,
#ab5386) from Abcam (Cambridge, MA) and anti-phospho-
tyrosine (4G10) (1:3000, #16-316) from Milipore Corporation
(Billerica, MA).
Ephrin-A5 preparation and treatment
Recombinant ephrin-A5-Fc protein was purchased from R&D
Systems (Minneapolis, MN, USA; #374-EA). To form clustered
ephrin-A5, ephrin-A5-Fc (2 mg/mL) was cross-linked with anti-
human Fc IgG (Jackson Immuno-Research, Immuno-Research,
West Grove, PA, USA) at a 5:1 ratio in mgs for 2 hours at 37uCa s
described in our previous studies [71]. Transfected cells were
stimulated by ephrin-A5-Fc after serum starvation at 37uC
overnight.
Western blot analysis
Tissue and cells were lysed in lysis buffer containing 50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP-40, 100 mg/mL
phenylmethylsulfonyl fluoride (PMSF), 1 mg/mL aprotinin,
10 mg/mL leupeptin, and 1 mM Na3VO4 for 30 minutes at
4uC. Lysates were cleared by centrifugation at 13,000 g for
2 minutes. 30 mg of protein samples were boiled in 2| SDS-
PAGE loading buffer and fractionated on 7.5% (w/v) SDS-PAGE
gels and transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA). After blocking with 5% (w/v) dried skim
milk in PBST (PBS with 0.1% Tween 20) for 1 hour, the
membranes were probed with the indicated antibodies, coupled
with a HRP-conjugated secondary antibody. Bands were visual-
ized with chemiluminescence using ECL western blotting
detection reagents (Amersham Pharmacia Biotech, UK) according
to the manufacturer’s instructions. Protein band intensities were
quantified using NIH ImageJ software.
Immunoprecipitation
Briefly, various antibodies were added to the cell lysate, and
incubated at 4uC overnight. The immunocomplex was recovered
by using protein A-agarose beads (Roche Molecular Biochemicals,
Indianapolis, IN, USA; #1719408) and centrifugation. After
washing the protein A-Agarose beads five times with lysis buffer,
the precipitated proteins were recovered by boiling in 40 mL2 |
SDS-PAGE loading buffer for 5 minutes.
Detection of ubiquitination
HEK293T cells at 80% confluence were co-transfected with
2 mgo fEPHA2 plasmid DNA and 1 mg of HA-tagged ubiquitin
(HA-Ub) using the Lipofectamine 2000 (Invitrogen, Carlsbad, CA,
USA). At 48 hours post-transfection, cells were treated with
10 mM MG132 for 6 hours, and then were lysed with cell lysis
Buffer. Cell lysates were clarified at 13,000 g for 2 minutes.
Immunoprecipitation was carried out using an EphA2 antibody at
1 mg/mg of total protein at 4uC for 2 hours. Immune complexes
were collected using protein A agarose (Millipore, Billerica, MA,
USA) at 4uC for 1 hour. The beads were then washed with
immunoprecipitation wash buffer containing 20 mM Tris-HCl
(pH 7.4), 10% glycerol, 50 mM NaCl, 0.2% NP-40, 0.5 mM
PMSF and 0.5 mM Na3VO4. The samples were re-suspended in
SDS sample buffer and fractionated on 7.5% polyacrylamide gel.
Immunoprecipitates or total cell lysates were analysed by western
blotting as described above and probed with the anti-HA-Tag
antibody.
Inhibition of protein synthesis and degradation
HEK293T cells were transfected with the EPHA2 wild-type and
four mutants, c.2819C.T, c.2915_2916delTG, c.2826-9G.A,
and c.2842G.T. At 48 hours post-transfection, the culture media
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treated with the protein biosynthesis inhibitor CHX at 50 mg/mL,
the proteasome inhibitor MG132 at 10 mM or the lysosomal
inhibitor bafilomycin A1 at 100 nM, incubated for various times,
then lysed. Total cell lysates were analysed by western blotting as
described above.
Expression of glutathione S-transferase (GST) fusion
protein and GST pull-down assay
The following primer pairs containing Sma I for forward primer
and Not I for reverse primer were used to generate GST-tagged
recombinant plasmids: wild-type EPHA2 SAM domain, Forward
primer 59-tgttgcccgggattccgcacggtgtccgagtg-39 and reverse primer
59-ccttctcgagtcaagtgttcacctggtcctt-39; and mutant EPHA2 SAM
domains, forward primer 59-tgttgcccgggattccgcacggtgtccgagtg-39
and reverse primer 59-ccttctcgagtcagaaataaataaagtcccc-39. PCRs
were performed with the following cycle conditions: 95uC for
30 sec, 54uC for 30 sec, and 72uC for 30 sec for 25-cycles. PCR
products were cloned into pGEX5X-1 expression vector. All GST-
tagged SAM domain constructs were transformed into BL21
(DE3) E. coli, the proteins were induced with 1 mM isopropyl-b-D-
thiogalactoside (IPTG) at 37uC for 4 hours. Whole-cell extracts
were prepared and separated into soluble and insoluble fractions,
and then the amount of recombinant GST fusion proteins were
determined by coomassie or silver staining. For GST-wild-type
SAM, GST-c.2819C.T SAM and GST-c.28442G.T SAM, 66
amino acids from the EphA2 SAM domain were fused to GST in
frame at the 39 end, resulting fusion proteins with the molecular
weight of 33.6 kDa. For GST-c.2915_2916delTG SAM and GST-
c.2826-G.A SAM, the mutated SAM domains contain 105
amino acids and 108 amino acids, respectively, resulting in
molecular weights of 38 and 38.2 kDa.
RNA preparation, reverse transcription (RT)-PCR and real-
time PCR
To study the transcription of the EPHA2 plasmids using semi-
quantitative RT-PCR, total RNA was isolated from transfected
cells using a QIAGEN total RNA isolation kit (Valencia, CA,
U.S.A.). cDNA was generated by reverse transcription reaction
using 5 mg of total RNA per sample with random primers and the
SuperScript II Reverse Transcriptase kit (Invitrogen, Carlsbad,
CA, USA). The following primer pairs were used for the analysis
of EPHA2 levels using PCR, generating a product of 248 bp:
EPHA2, forward primer 59-ttgtcatgtgggaggtgatg-39 and reverse
primer 59-aaagtcagccagggtcttg-39; and GAPDH, forward primer
59-ttgccatcaatgaccccttca-39 and reverse primer 59-cgccccactt-
gattttgga-39. PCRs were performed with the cycle conditions of
95uC for 30 sec, 60uC for 30 sec, and 68uC for 30 sec for 25
cycles.
Real-time PCR was performed using the ABI PRISMH 7000
sequence detection system and PCR reactions including SYBR
Green dye. Results for target genes were normalized to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA
expression for each sample, and relative expression was calculated
using the comparative threshold cycle method [72].
Immunofluorescence staining
EphA2
2/2 MEF (E13.5) cells expressing wild-type and mutant
EPHA2 genes were serum-starved overnight and then incubated
with 2 mg/mL cross-linked ephrin-A5-Fc for 30 minutes. Cells
were washed twice with phosphate buffered saline (PBS) at room
temperature, and fixed in 4% paraformaldehyde (PFA) on ice for
30 minutes. Cells were permeablized with 0.3% PBS including
Tween-20, and then blocked with 5% goat serum at room
temperature for 2 hours. Secondary antibody Biotin-SP-AffiniPure
goat anti-human IgG (Jackson Immuno-Research, Immuno-
Research, West Grove, PA, USA) incubations were performed
at room temperature for 1 hour. After extensive washing with
PBS, CY3-conjugated streptavidin (Jackson Immuno-Research,
Immuno-Research, West Grove, PA, USA) was added for 2 hours.
Subsequently, samples were washed again with PBS and then
incubated with anti-EphA2 antibody (1:200, Abcam, Cambridge,
MA), and images of stained cells were captured with a Nikon
Eclipse C1 confocal microscope with 200| magnification.
Cell migration assay
HEK293A cells were seeded on collagen-coated dishes and
cultured for 24 hours. Cells expressing wild-type or mutant
EPHA2 constructs were serum-starved overnight. GFP-expressing
vector, pEGFP-N1 was cotransfected with the EPHA2 clones to
identify transfected cells in the wound-healing assay. For ligand
treatments, the culture media were replaced with fresh
DMEM+10% FBS prior to stimulation. Cells were stimulated
with 2 mg/mL cross-linked ephrin-A5-Fc. The migration distances
of cells were monitored at the indicated time points (0, 24, and
48 hours) after wounding and quantified as described [73]. Images
were captured using a Nikon Eclipse C1 confocal microscope with
40| magnification. The relative migration distance of GFP-
positive cells into wound was determined using NIH ImageJ and
Adobe Photoshop CS3 software.
Statistical analysis
Statistical analyses were performed using the PrismH software
(GraphPad Software, La Jolla, CA). Statistical differences between
multiple groups were analyzed using one-way analysis of variance
(ANOVA). A two-tailed student t-test was used to analyze
statistical significance between two groups. All values are
presented as the standard deviation of the mean (+S.D.) from
at least three independent experiments. Value of P,0.05 was
considered to be statistically significant.
Supporting Information
Figure S1 EPHA2 cataract mutations reduce SAM
domain solubility in E. coli. GST alone and GST-fusion
proteins containing either wild-type SAM domain, two missense
mutations c.2819C.T SAM and c.2842G.T SAM, the frame-
shift mutation c.2916_2916delTG SAM, and the splicing mutation
c.2826-9G.A SAM were overexpressed in BL21 (DE3) E. coli
with 1 mM IPTG at 37uC for 4 hours. (A) GST-fusion proteins
were highly induced in bacterial cells by IPTG treatment. After
induction with 1 mM IPTG, whole-cell extracts were prepared
fractionated with SDS-PAGE, and stained with Coomassie Blue.
(B) The solubility of the EPHA2 mutant proteins was significantly
reduced. Whole-cell extracts were separated into soluble (S) and
insoluble (I) fractions, and then the amount of soluble and
insoluble recombinant GST fusion proteins were determined by
silver staining. Arrowheads indicate the position of the fusion
proteins.
(TIF)
Figure S2 EPHA2 degradation is mediated by proteaso-
mal pathway. (A) MG132 prevents degradation of EPHA2
protein. HEK293T cells were treated for indicated time with the
protein biosynthesis inhibitor CHX (50 mg/mL) and the protea-
some inhibitor MG132 (10 mM). Cell lysates were immunoblotted
with anti-EphA2 antibody. Lysates were resolved by SDS-PAGE
and western blot analysis was performed using indicated
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was reprobed with anti-a-tubulin as a loading control. (B) Graphs
show EphA2 protein levels over time. Mean values are presented
with +S.D as indicated.
(TIF)
Figure S3 Bafilomycin A1 does not stabilize EPHA2
protein. HEK293T cells were transfected and treated for
indicated time with the lysosomal inhibitor bafilomycin A1
(100 nM). Cell lysates were immunoblotted with anti-EphA2
antibody. Lysates were resolved by SDS-PAGE and western blot
analysis was performed as described in the Materials and Methods.
The blot was reprobed with anti-a-tubulin as a loading control.
(TIF)
Figure S4 SAM domain of EPHA2 is essential for ligand-
independent promotion of cell migration of HEK293A
cells. (A) EPHA2 SAM domain mutants lack migration promoting
activity in HEK293A cells. HEK293A cells were grown to
confluence and serum-starved for 24 hours. A scratch wound
was made with a micropipette tip and the edge of cells as marked.
2 mg/mL cross-linked ephrin-A5-Fc was then added to the
starvation media, and cells were allowed to migrate toward the
center of the wound and photographed at the indicated times
(representative figure of three independent experiments). The
position of the initial scratch is indicated by dotted lines. Scale bar,
500 mm. (B) Quantification of EPHA2 genes on HEK293A cell
migration. The graphs represent the measurement of migration
distance from three independent experiments. Mean values are
presented with +S.D as indicated. Statistical differences were
analyzed using one-way analysis of variance (ANOVA) or
calculated by a two-tailed student t-test. Black asterisks,
comparison between time 0 and 24 hours and time 0 and
48 hours; Blue asterisks, comparison between the mock groups
and the listed wild-type or mutant EPHA2 genes at 24 or 48 hours;
Red asterisks, comparison between untreated and treated
conditions at 24 or 48 hours. ***, P,0.001; **, P,0.01; *,
P,0.05; and ns, not significant. Values of P,0.05 were considered
to be statistically significant.
(TIF)
Figure S5 Ligand-stimulated EPHA2 activation regu-
lates Akt activation in aTN4-1 cells. (A) Mutant EPHA2
genes have reduced ability to activate Akt. aTN4-1 cells were
grown to near confluence, and growth factor-starved for 24 hours.
2 mg/mL cross-linked ephrin-A5-Fc was then added to the
starvation media and cell lysates were immunoblotted with
indicated antibodies. The blot was probed with anti-phospho-
Akt (Ser473), and then reprobed with anti-a-tubulin as a loading
control. (B) Wild-type and mutant EPHA2 genes have similar
activity in Akt activation when corrected for EPHA2 protein
levels. Graphs show ratio of phosphor-Akt to total EPHA2.
Quantification of phospho-Akt protein/total EPHA2 protein was
determined using ImageJ software. Mean values are presented
with +S.D as indicated. Statistical differences between multiple
groups were analyzed using one-way analysis of variance
(ANOVA). Values of P,0.05 were considered to be statistically
significant. ns: No statistically significant difference between the
two groups. Data for the other two mutants were not quantified,
due to the very low levels of the signals.
(TIF)
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